Further reading:
http://www.biolinerx.com/uploaded/BL-1020%20(Cognition%20need%20GABA%20mechanism)%20(Meltzer)%20(final).pdf
Y Geffen, R Keefe, J Rabinowitz, R Anand and M Davidson,
The Journal of clinical psychiatry , Sep 2012
BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity. On the basis of animal models, we tested the hypotheses that BL-1020 would be effective in ameliorating both psychotic symptoms and cognitive impairments, with a favorable safety profile in acutely ill schizophrenia patients.363 hospital-based psychiatric patients in India, Romania, and United States aged 18 to 65 years and meeting criteria for DSM-IV-TR diagnosis of chronic schizophrenia were randomized double-blind to receive BL-1020 10 mg/d, BL-1020 20-30 mg/d, placebo, or risperidone (2-8 mg/d) for 6 weeks. The main outcome measures were the positive and negative syndrome scale (PANSS), brief assessment of cognition in schizophrenia, readiness for discharge questionnaire, clinical global impressions scale (CGI) , and extrapyramidal symptom rating scale. The study ran from July 2008 to June 2009.BL-1020 20-30 mg was significantly better than placebo on PANSS (P = .02) and CGI (P < .001) measurements, with no significant differences noted between BL-1020 20-30 mg and risperidone. There were no significant differences in the maximum change on extrapyramidal symptom rating scale between risperidone and BL-1020 20-30 mg, and both were significantly worse (P < .001) than placebo. BL-1020 20-30 mg was associated with significantly greater improvements on cognitive functioning as measured by the brief assessment of cognition in schizophrenia composite score when compared to placebo (effect size = 0.50, P = .009), risperidone (effect size = 0.43, P = .019), and BL-1020 10 mg (effect size = 0.42, P = .013) after 6 weeks.BL-1020 appears to be an effective antipsychotic with possible procognitive effects that will need to be further tested for short- and long-term effects. A further randomized controlled trial using the U.S. Food and Drug Administration-recommended Measurement and Treatment Research to Improve Cognition in Schizophrenia cognitive battery is ongoing.ClinicalTrials.gov identifier: NCT00567710.
1 Like
Good info – thanks for sharing.
Clint
May 22, 2016, 4:43pm
5
Is BL-1020 back in play? Do you have any information to share on recent developments?
The last I heard, the last trial was unsuccessful, but they were hanging onto the rights and still considering a possible future for the substance. Are you indicating that Biolinerx is developing BL-1020 again?
@Clint
It’s the first time I hear about this drug. I didn’t know he had disappointing results in later trials. As you see, the news I posted is from late 2012.
1 Like
Clint
May 22, 2016, 5:40pm
7
Well, some people may have considered the results of the middle of the last trial to be ‘disappointing,’ but, I think the company may start developing it again in the future. I still have hope for it.
http://www.biolinerx.com/default.asp?pageid=16&itemid=180